Linaprazan

Cat. No.: HY-100412
CAS No.: 248919-64-4
Molecular Formula: C₂₁H₂₆N₄O₂
Molecular Weight: 366.46
Target: Proton Pump
Pathway: Membrane Transporter/Ion Channel
Storage:
- Powder: -20°C, 3 years
- 4°C: 2 years
- In solvent: -80°C, 2 years; -20°C, 1 year

**SOLVENT & SOLUBILITY**

**In Vitro** DMSO: ≥ 35 mg/mL (95.51 mM)
* "≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing</th>
<th>Concentration</th>
<th>Mass (mL)</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock</td>
<td>1 mM</td>
<td></td>
<td>2.7288</td>
<td>13.6441</td>
<td>27.2881</td>
</tr>
<tr>
<td>Stock</td>
<td>5 mM</td>
<td></td>
<td>0.5458</td>
<td>2.7288</td>
<td>5.4576</td>
</tr>
<tr>
<td>Stock</td>
<td>10 mM</td>
<td></td>
<td>0.2729</td>
<td>1.3644</td>
<td>2.7288</td>
</tr>
</tbody>
</table>

Prepare the stock solutions using the appropriate solvent concentration and adjust the mass according to the desired concentration.

Linaprazan (AZD0865) inhibits gastric H⁺,K⁺-ATPase by K⁺-competitive binding. (IC₅₀: 1.0 ± 0.2 μM) It is an acid-suppressing agent with rapid onset of action and potent acid inhibition. In vitro: Linaprazan can inhibit the final step in acid secretion. Linaprazan reduced porcine renal Na⁺,K⁺-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H⁺,K⁺-ATPase. In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks.

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898                        Fax: 609-228-5909                        E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA